GSK eyes life after a patent cliff
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline is shifting "from being a blockbuster-dependent" company that relies on a single patented drug for a bulk of its revenue to a "blockbuster-ready" firm with a well-diversified portfolio that provides protection if the next big drug comes too late to offset generic competition for the current top-seller, CEO Andrew Witty says. At Cowen & Co.'s Health Care Conference March 17 in Boston, Witty said GSK is seeking diversity rather than the next blockbuster drug to "diminish the possibility of simply going back to another patent cliff," like the one it fell off last year when it lost exclusivity for several prescription drugs. GSK will invest in multiple small prescription drugs and seeks bolt-on acquisitions of vaccines and brands in "the consumer emerging market" to reduce the impact of any one patent expiry, Witty said (1"The Tan Sheet" Feb. 9, 2009, p. 9)
You may also be interested in...
GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
Prop 65 Warnings Intended For Small Spaces But Used On Luggage? California Proposes Limits
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: